Benzylthiouracil induced anca associated glomerulonephritis in patients with graves ‘disease

##plugins.themes.academic_pro.article.sidebar##

Published Jan 12, 2016
Download
pdf
Vol. 93 No. 11 (2015): Issue Nov 2015

##plugins.themes.academic_pro.article.main##

Hayet Kaaroud
Ibtissem Oueslati
Amel Harzallah
Ibtissem Ben Nacef
Karima Khiari
Fethi Ben Hamida

Abstract

SUMMARY
Background: Renal complications in Graves’ disease are rare and may be related either to the disease itself or secondary to antithyroid drugs.
Aim: We report 6 cases of renal damage in patients with Graves' disease treated with Benzylthiouracil collected over a period of 14 years.
Methods: There were 6 women with a mean age of 37.86 ± 14.25 years. All patients developed renal vasculitis associated with ANCA. The signs were dominated by renal proteinuria and renal failure associated with hematuria in all cases. The lung involvement was the most common extrarenal manifestation occurred in 4 patients (alveolar hemorrhage in 2 cases, lymphocytic alveolitis in 1 case and pleurisy in 1 case). The benzylthiouracil was discontinued in 3 patients still under treatment. Corticosteroid therapy was used alone or in combination with cyclophosphamide in all cases. Plasmapheresis sessions were made during the alveolar hemorrhage. A complete remission was obtained in one case and incomplete remission in 2 cases. The other 3 patients required chronic hemodialysis. One patient died of sepsis.
Conclusion: The possibility of renal impairment in antithyroid drugs treated Graves' disease requires monitoring to detect urinary abnormalities in order to early initiate therapy and improve patient’s outcome.

Keywords:

Graves'disease, benzylthiouracil, glomerulonephritis, vasculitis, ANCA.

##plugins.themes.academic_pro.article.details##

References

  1. Kaaroud H, Khiari K, Ben Moussa F et al. Vasculitis with renal and pulmonary involvement in a patient receiving benzylthiouracil for Graves' disease. Rev Méd Int 2002; 23:857-61.
  2. Braham A, Houmen MH, Rais L et al. Benzylthiouracil induced ANCApositive vasculitis. Presse Méd 2004; 33: 1331-3.
  3. Frigui M, Kechaou M, Haddouk S et al. Benzylthiouracil induced ANCApositive vasculitis: study of three cases and review of the literature. Ann Endocrinol 2008; 69 (suppl 6): 517-22.
  4. Trimeche Ajmi S, Braham R, Toumi S et al. Benzylthiouracil-induced glomerulonephritis. Case Rep Med 2009; 2009: 687285.
  5. Baili L, Aydi Z, Daoud F et al. Benzylthiouracil induced ANCA-positive vasculitis. Tunis Med 2014 ; 92 (suppl 6) : 428-430.
  6. Stankus SJ, Johnson NT. Propylthiouracil-induced hypersensitivity vasculitis presenting a respiratory failure. Chest 1992; 102: 1595-6.
  7. Dolman KM, Grans RO, Vervaat TJ et al. Vascularitis and antineutrophil cytoplasmic antibodies associated with propylthiouracil therapy. Lancet 1993; 342:651-2.
  8. Tieulie N, Huong DL, Andreu M et al. ANCA associated glomerulonephritis related to benzylthiouracil. Rev Med Interne 2002; 23 (suppl 10):853-6.
  9. Gunton JE, Stie lJ, Clifton-Bligh P, Wilmshurst E, McElduff A. Prevalence of antineutrophil cytoplasmic antibody (ANCA) in patients receiving antithyroid medication. Eur J Endocrinol 2000; 142:587-94.
  10. Lam DC, Lindsay RH. Accumulation of 2- (14C) propylthiouracil in human polymorphonuclear leucocytes. Biochem Pharmacol. 1979; 28: 2289-96.
  11. Lee H, Hirouchi M, Hoso Kawa M et al. Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol 1988; 37: 2151-3.
  12. Harper L, Cockwell P, Savage CO. Case of propylthiouracil-induced ANCA associated small vessel vasculitis. Nephrol Dial Transplant 1998; 13 (suppl 2):455-8.
  13. Waldhauser L, Uterech J. Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis. Drug Metab Dispos1991; 19: 354-9.
  14. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87:4115-19.
  15. Keogan MT, Esnault VL, Green AJ, Lckwood CM, Brown DL. Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies. Clin Exp Immunol 1992; 90: 228-34.
  16. Papo T, Huong D, Piette JC, Godeau P. Les anticorps anticytoplasme des polynucléaires neutrophiles sont-ils pathogènes ? Rev Med Int 1994; 15:110-5.
  17. Haapla AM, Soppi E, Hyoty H, Mustonen J, Pasternack A. Crossreactivity between antibodies to thyroid microsomal antigens and Myeloperoxydase. Lancet 1991; 337: 803-4.
  18. Mariotti S, Anelli S, Ruf J et al. Comparison of serum thyroid microsomial and thyroid peroxydase autoantibodies in thyroid diseases. J clin Endocrinol Metab 1987; 65:987-93.
  19. Kimura S, Ikeda SM. Human myeloperoxydase and thyroid peroxidase, two enzymes with separate and distinct physiological functions, are evolutionarily related members of the same gene family. Proteins 1988; 3: 113-20.
  20. Sato H, Hattori M, Fujieda M et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000; 85(suppl 11): 4270-3.
  21. Honda H, ShibataT, Hara H, Ban Y, Sugisaki T. Antineutrophil cytoplasmic antibodies in patients with Graves' disease: association of antimyeloperoxidase autoantibodies with propylthiouracil therapy. Mod Rheumatol 2003; 13(suppl 4):305-
  22. Kallemberg CGM, Mulder AHL, Cohen TJW. Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. Am J Med 1992; 93:675-82
  23. Jacob CO, Fronek Z, Lewis GD et al. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990; 87: 1233-7.
  24. Kallenberg CGM, Brovwer E, Weening JJ, Tervaet JWC. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46:1-15
  25. Fuji A, Tomizaka K, Arimura Y et al. Epitope analysis of myeloperoxydase specific ANCA (MPO-ANCA) associated glomerulonephritis. Clin Nephrol 2000; 53: 242-52.
  26. Porges AJ, Redecha PB, Csernok E, Gross WL, Kimberly RP. Antineutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol 1994; 153 (suppl 3):1271-80.
  27. Weetman AP, Tomlison K, Amos N et al. Proteinuria in autoimmune thyroid disease. Acta Endocrinol 1985; 109 (suppl 3): 341-7.
  28. Tenemoto M, Miyakawa H, Hanai J et al. Myeloperoxidase-ANCA positive crescentic glomerulonephritis complicating the course of Graves' disease: report of three adult cases. Am J Kidney Disease 1995;26 (suppl 5): 774-80.
  29. Noh JY, Asari T, Hamada N et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol 2001; 54 (suppl 5): 651-4.
  30. Yazisiz V, Ongut G, Terzioglu E, Karyalcin U. Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment. Int J Clin Pract 2010; 64(suppl 1):19-24.
  31. Wada N, Mukai M, Kohno M et al. Prevalence of serum antimyeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. Endocr J 2002; 49 (suppl 3): 329-34.
  32. Sghiri M, Ouertani M, Ben Hsine H et al. Prevalence of antineutrophil cytoplasmic antibody during treatment with Benzylthiouracil. Pathol Biol 2009; 57(suppl 5): 410-4.
  33. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368: 404-18.
  34. Slot MC, Links TP, Stegeman CA, Tervaert JW. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long follow up study. Arthritis Rheum 2005; 53(suppl 1):108-13
  35. Gunton JE, Stiel J, Caterson RJ, McElduff A.Clinical case seminar: Antithyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab 1999; 84(suppl 1):13-6.
  36. Tervaert JW, van der Woude FJ, Fauci AS et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149 (suppl 11): 2461-5.